Biosimilar vs Generic — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — A biosimilar is highly similar to its reference biologic, without clinically meaningful differences, whereas a generic contains the same active substance as its reference medicine and is demonstrated to be bioequivalent.
Explanation lettering: D = shown as A · C = shown as B · A = shown as C · E = shown as D · B = shown as E
A is correct. Biologics are large, complex products made using biological systems, so a biosimilar is established through a comprehensive analytical, functional and pharmacokinetic comparability exercise. It must be highly similar to the reference biologic, and any differences must have no clinically meaningful effect on safety or efficacy. By contrast, a UK generic has the same active substance and pharmaceutical form as its reference medicine and is ordinarily licensed by demonstrating bioequivalence. Biosimilars are therefore not exact molecular copies, excluding B. Option C reverses the regulatory pathways. Biosimilars undergo formal MHRA assessment, excluding D. They cannot retain clinically meaningful efficacy differences, and generics do not normally repeat the reference product's efficacy trials, excluding E.
Reference: NHS Specialist Pharmacy Service. Understanding biological and biosimilar medicines, section 'Differences between generic medicines and biosimilars'. Updated 2025. https://sps.nhs.uk/articles/understanding-biological-and-biosimilar-medicines/